Cargando…

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis

Anaplastic thyroid carcinoma (ATC) is difficult to distinguish from other cancers, especially when its pathological features are atypical for ATC or when the tumor is totally undifferentiated and occurs after a considerable lapse of time, in an area remote from the original site of the tumor. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Young Shin, Jung, Chan Kwon, Jung, Kyeong Cheon, Park, Young Joo, Won, Jae-Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592191/ https://www.ncbi.nlm.nih.gov/pubmed/28875621 http://dx.doi.org/10.3346/jkms.2017.32.10.1721

Ejemplares similares

Correlation of Immunohistochemical Markers and BRAF Mutation Status with Histological Variants of Papillary Thyroid Carcinoma in the Korean Population
por: Min, Hye Sook, et al.
Publicado: (2013)

Clinicopathological Features of Rare BRAF Mutations in Korean Thyroid Cancer Patients
por: Cho, Uiju, et al.
Publicado: (2014)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
por: Hong, A Ram, et al.
Publicado: (2014)

The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma
por: Kim, Hyeon Jin, et al.
Publicado: (2017)

Can Ultrasound Be as a Surrogate Marker for Diagnosing a Papillary Thyroid Cancer? Comparison with BRAF Mutation Analysis
por: Seo, Jae Young, et al.
Publicado: (2014)

Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis
por: Park, Ji Hye, et al.
Publicado: (2014)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma
por: Kong, Joon Seog, et al.
Publicado: (2018)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

Acute pyelonephritis with anaplastic thyroid carcinoma producing granulocyte colony-stimulating factor
por: Kang, Keunhee, et al.
Publicado: (2013)

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio before and after Radiotherapy for Anaplastic Thyroid Carcinoma
por: Park, Jiyun, et al.
Publicado: (2021)

Anoctamin-1 affects the migration and invasion of anaplastic thyroid carcinoma cells
por: Kim, Jae-Young, et al.
Publicado: (2019)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
por: Basnet, Alina, et al.
Publicado: (2017)

Leukemic manifestation of anaplastic lymphoma kinase-negative-type anaplastic large-cell lymphoma
por: Kim, Jae Wook, et al.
Publicado: (2012)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAF(V600E) mutations in papillary thyroid carcinoma
por: Yoon, Jung Hyun, et al.
Publicado: (2020)

Comparison of clinicopathological characteristics and survival between symptomatic and asymptomatic anaplastic thyroid carcinoma
por: Cho, Seomin, et al.
Publicado: (2023)

Anaplastic Thyroid Carcinoma
por: Taccaliti, Augusto, et al.
Publicado: (2012)

BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer
por: Han, Sang-Ah, et al.
Publicado: (2014)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

Targeting the BRAF Signaling Pathway in CD133(pos) Cancer Stem Cells of Anaplastic Thyroid Carcinoma
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2019)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis
por: Li, Xin, et al.
Publicado: (2020)

p53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas
por: Nakamura, Tsutomu, et al.
Publicado: (1992)

Erratum: Correction of Nomenclature of BRAF Mutation
por: Cho, Uiju, et al.
Publicado: (2014)

Curcumin Enhances Docetaxel-Induced Apoptosis of 8505C Anaplastic Thyroid Carcinoma Cells
por: Hong, Jung Min, et al.
Publicado: (2014)

Epigenetic modification and BRAF gene mutation in thyroid carcinoma
por: Huang, Guo, et al.
Publicado: (2021)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
por: Lim, Jinsun, et al.
Publicado: (2023)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
por: Ishihara, Sae, et al.
Publicado: (2019)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Anaplastic Thyroid Carcinoma: An Update
por: Jannin, Arnaud, et al.
Publicado: (2022)

Is Follow-up BRAF(V600E) Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
por: Yoon, Jung Hyun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_48nberi8972o6utivokvgk4ndv